HCA Healthcare (HCA) Stock Forecast & Price Target

$404.74 +0.48 (+0.12%)

As of 03:30 PM Eastern

HCA Healthcare - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 17 Analyst Ratings

Sell
0

Hold
9

Buy
8

Based on 17 Wall Street analysts who have issued ratings for HCA Healthcare in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 17 analysts, 9 have given a hold rating, 7 have given a buy rating, and 1 has given a strong buy rating for HCA.

Consensus Price Target

$398.58
-1.52% Downside

According to the 17 analysts' twelve-month price targets for HCA Healthcare, the average price target is $398.58. The highest price target for HCA is $440.00, while the lowest price target for HCA is $370.00. The average price target represents a forecasted downside of -1.52% from the current price of $404.74.

Get the Latest News and Ratings for HCA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for HCA Healthcare and its competitors.

HCA Analyst Ratings Over Time

Type	Current Forecast 8/22/24 to 8/22/25	1 Month Ago 7/23/24 to 7/23/25	3 Months Ago 5/24/24 to 5/24/25	1 Year Ago 8/23/23 to 8/22/24
Strong Buy	1 Strong Buy rating(s)	2 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	7 Buy rating(s)	9 Buy rating(s)	11 Buy rating(s)	14 Buy rating(s)
Hold	9 Hold rating(s)	8 Hold rating(s)	6 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$398.58	$399.21	$381.13	$354.67
Forecasted Upside	-1.52% Downside	13.13% Upside	1.14% Upside	-7.44% Downside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

HCA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HCA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

HCA Healthcare Stock vs. The Competition

Type	HCA Healthcare	Medical Companies	S&P 500
Consensus Rating Score	2.53	2.79	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	-1.87% Downside	13,210.32% Upside	9.56% Upside
News Sentiment Rating	Positive News See Recent HCA News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/14/2025	Robert W. Baird 2 of 5 stars	Michael Ha Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$380.00 ➝ $423.00	+8.09%
8/14/2025	Wells Fargo & Company 3 of 5 stars	Stephen Baxter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$385.00 ➝ $375.00	-3.76%
8/4/2025	JPMorgan Chase & Co. 2 of 5 stars	Benjamin Rossi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$360.00 ➝ $370.00	+1.89%
7/28/2025	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Justin Lake Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Peer Perform
7/28/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Ben Hendrix Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$404.00 ➝ $401.00	+19.57%
7/28/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andrew Mok Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$416.00 ➝ $390.00	+16.29%
7/28/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Craig Hettenbach Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$410.00 ➝ $400.00	+19.67%
7/16/2025	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	David MacDonald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$390.00 ➝ $415.00	+15.14%
7/16/2025	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Kevin Fischbeck Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$394.00	+6.00%
6/2/2025	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Kumar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
Get the Latest News and Ratings for HCA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for HCA Healthcare and its competitors with MarketBeat's FREE daily newsletter.
4/15/2025	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Ha Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/9/2025	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jason Cassorla Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral
1/27/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Sarah James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$405.00 ➝ $405.00	+29.60%
1/7/2025	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Gillmor Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$420.00 ➝ $370.00	+20.54%
11/22/2024	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Ransom Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
10/28/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$450.00 ➝ $440.00	+22.05%
10/28/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$390.00 ➝ $400.00	+10.22%
8/14/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$405.00 ➝ $438.00	+18.74%
7/24/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$367.00 ➝ $396.00	+16.32%
6/28/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$359.00 ➝ $375.00	+14.85%
1/4/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$277.00 ➝ $301.00	+9.85%
12/11/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$271.00	+5.23%
10/25/2023	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$325.00 ➝ $275.00	+21.19%
10/25/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$324.00 ➝ $279.00	+22.87%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 03:30 PM ET.

Should I Buy HCA Healthcare Stock? HCA Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, August 20, 2025. Please send any questions or comments about these HCA Healthcare pros and cons to contact@marketbeat.com.

HCA Healthcare
Bull Case

Here are some ways that investors could benefit from investing in HCA Healthcare, Inc.:

The company recently reported strong quarterly earnings, with earnings per share (EPS) of $6.84, surpassing analysts' expectations significantly. This indicates robust financial performance and potential for future growth.
HCA Healthcare, Inc. has set a positive guidance for fiscal year 2025, projecting EPS between 25.500 and 27.000, suggesting confidence in continued profitability.
The current stock price is around $400, reflecting a solid market position and investor interest, which could indicate potential for appreciation.
Analysts have a consensus rating of "Moderate Buy" for the stock, with several recent upgrades in price targets, indicating positive sentiment in the market.
The company has a low dividend payout ratio of 12.11%, allowing for reinvestment in growth opportunities while still providing a dividend yield of 0.7% to shareholders.

HCA Healthcare
Bear Case

Investors should be bearish about investing in HCA Healthcare, Inc. for these reasons:

The company has a negative return on equity of over 7,363%, which may raise concerns about its efficiency in generating profits from shareholders' equity.
HCA Healthcare, Inc. has a relatively high debt-to-equity ratio of 69.07, indicating that the company is heavily reliant on debt financing, which could pose risks in a rising interest rate environment.
Despite recent earnings growth, the stock has experienced volatility, with a 1-year high of $417.14 and a low of $289.98, suggesting potential instability in its market performance.
Some analysts have downgraded their ratings, reflecting mixed sentiments about the stock's future performance and potential challenges in the healthcare sector.
The healthcare industry is facing regulatory pressures and uncertainties, which could impact HCA Healthcare, Inc.'s operations and profitability in the long term.

HCA Forecast - Frequently Asked Questions

: According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for HCA Healthcare is $398.58, with a high forecast of $440.00 and a low forecast of $370.00.
: 17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for HCA Healthcare in the last year. There are currently 9 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HCA shares.
: According to analysts, HCA Healthcare's stock has a predicted downside of -1.52% based on their 12-month stock forecasts.
: Over the previous 90 days, HCA Healthcare's stock had 2 upgrades and 2 downgrades by analysts.
: HCA Healthcare has been rated by research analysts at Bank of America, Barclays, JPMorgan Chase & Co., Morgan Stanley, Robert W. Baird, Royal Bank Of Canada, Stephens, Truist Financial, Wells Fargo & Company, and Wolfe Research in the past 90 days.
: Analysts like HCA Healthcare less than other "medical" companies. The consensus rating score for HCA Healthcare is 2.53 while the average consensus rating score for "medical" companies is 2.79. Learn more on how HCA compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:HCA) was last updated on 8/22/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HCA Healthcare (HCA) Stock Forecast & Price Target